- Trial phase
- Approved
- Time to market
- Already approved and commercialized (FDA approval December 2018)
- Why 4/10
- FIRDAPSE is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout for this drug. The next hard catalyst for the stock is the Angelini Pharma acquisition closing (expected Q3 2026 at $31.50/share), which is a corporate M&A event, not a drug catalyst. Per the impact score rubric, an approved drug with no imminent new binary catalyst scores 3-5 regardless of revenue size or strategic importance.
FIRDAPSE is a cash-generating approved product with patent protection into 2035, but CPRX stock is now primarily an acquisition-arbitrage vehicle: trading at ~$29.27 vs the $31.50 all-cash buyout by Angelini Pharma expected to close Q3 2026. The spread reflects deal-closing risk. There's no drug-specific binary catalyst; the thesis is purely M&A-driven from here.
Price Chart
Executive Summary
FIRDAPSE (amifampridine phosphate) is Catalyst Pharmaceuticals' flagship product, the first and only FDA-approved treatment for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune neuromuscular disorder. Approved in December 2018, it generated ~$358M in net product revenue in 2025 (17% YoY growth), with 2026 guidance of $435-450M. Patent settlements with Teva and Lupin block generic competition until 2035. However, the stock is now being acquired by Angelini Pharma for $31.50/share (~$4.1B all-cash), expected to close Q3 2026. With the drug already approved and no upcoming regulatory binary, FIRDAPSE itself is no longer a binary catalyst driver, the investment thesis has shifted to the buyout closing.
How It Works
FIRDAPSE is a potassium channel blocker that works at the connection point between nerves and muscles. In Lambert-Eaton myasthenic syndrome (LEMS), the immune system attacks these connection points, reducing the chemical signal (acetylcholine) that tells muscles to contract. FIRDAPSE blocks potassium channels in nerve endings, which prolongs the electrical signal and allows more of the muscle-contracting chemical to be released, thereby improving muscle strength.
Trial Status
FIRDAPSE was approved by the FDA in December 2018 for adults with LEMS, with subsequent label expansions for pediatric patients (6+) and higher dosing. Two pivotal Phase 3 placebo-controlled trials supported approval, demonstrating maintained muscle strength and improved patient-reported physical well-being. The drug is now the first-line recommended therapy for LEMS with a growing commercial footprint.
The Two-Sided Case
Upcoming Catalysts
- Angelini Pharma acquisition closing, expected Q3 2026; the definitive agreement at $31.50/share all-cash is the primary stock catalyst
- FIRDAPSE revenue growth trajectory as orphan-drug commercial execution continues; no specific clinical/regulatory readout dates remain for this approved drug
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CATALYST PHARMACEUTICALS, INC. DEFA14A CPRX ·Originating report